caption stringlengths 0 3.92k | molecule stringlengths 1 914 | properties listlengths 1 113 | additional_data dict |
|---|---|---|---|
The molecule is a nutrient. | CCCCC/C=C\C[C@H](O)/C=C/C=C/C=C\[C@H](O)CCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts seizure, cardiovascular disease, and parkinson's disease. It has an effect on colorectal cancer, and impacts alzheimer's disease, stomach cancer, and diabetes mellitus. | CCCCCCCCCCCCCCCC(=O)O[C@@H]1COC(=O)CCC/C=C\C[C@H]2C=CC(=O)[C@H](/C=C/[C@@H](O)CCCCC)[C@@H](O)[C@@H](O)[C@@H](OP(=O)(O)OC1)[C@H](O)[C@@H](O)[C@@H]2O | [
"Seizure",
"Cardiovascular disease",
"Parkinson's disease",
"Breast cancer",
"Colorectal cancer",
"Alzheimer's Disease",
"Stomach cancer",
"Diabetes mellitus"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts aging and diabetic heart disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Aging",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that affects breast cancer by impacting cervical cancer, atherosclerosis, and ulcerative colitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C[C@H]1[C@@H](O)CC(=O)[C@@H]1/C=C/[C@@H](O)CCCCC)COP(=O)([O-])OCC[N+](C)(C)C | [
"Cervical cancer",
"nutrient",
"Breast cancer",
"Atherosclerosis",
"Ulcerative colitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a avifuge and a fragrance, as well as glutathionalytic and insecticide. The molecule is a ec 3.1.1.7 (acetylcholinesterase) inhibitor, herbal, anti pyretic, and buchu. The molecule belongs to both the candidicide and nephrotoxic classes and is characterized as both fungicide and cerebrotoxic. The molecu... | CCCN=C(O)c1ccccc1 | [
"avifuge",
"glutathionalytic",
"insecticide",
"fragrance",
"EC 3.1.1.7 (acetylcholinesterase) inhibitor",
"herbal",
"anti pyretic",
"buchu",
"candidicide",
"fungicide",
"cerebrotoxic",
"nephrotoxic",
"cancer preventive",
"lime",
"sedative",
"camphor",
"pulmonotoxic",
"peppermint",
... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cancer treatment. | C=O.Cl.O=C(C1CCCO1)N1CCC(Oc2ccc(-c3ccc4cccnc4c3C3CC3)cc2)CC1 | [
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging and tangier disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Cholesterol translocation",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a emulsifier, a membrane stabilizer, and fruity. The molecule is a nutrient, a surfactant, a energy source, and green. The molecule is a energy storage, apple peel, applepeel, and sweet. The molecule is banana, pineapple, waxy, and fruit. | C=C(C(=O)OCCCC)C(C)O | [
"Emulsifier",
"Membrane stabilizer",
"fruity",
"nutrient",
"surfactant",
"Energy source",
"green",
"apple peel",
"applepeel",
"sweet",
"Energy storage",
"banana",
"pineapple",
"waxy",
"fruit"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both cardiovascular disease and pancreatitis. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both atherosclerosis and metabolic syndrome. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCCCCCCCC/C=C\CCCCCCCC | [
"Cardiovascular disease",
"Pancreatitis",
"Fat storage",
"Atherosclerosis",
"Metabolic syndrome",
"Thyroxine treatment",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts aging and tangier disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer that impacts pancreatitis, atherosclerosis, obesity, cardiovascular disease, and thyroxine treatment. The molecule is a fat storage that impacts both metabolic syndrome and cancer. The molecule is a inflammatory, energy source, energy storage, nutrient. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)COC(=O)CCCCCCCCCCCCCC(C)C | [
"Membrane stabilizer",
"Pancreatitis",
"Atherosclerosis",
"Obesity",
"Cardiovascular disease",
"Thyroxine treatment",
"Fat storage",
"Metabolic syndrome",
"Cancer",
"inflammatory",
"Energy source",
"Energy storage",
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease, tangier disease, and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, apoptosis that impacts barth syndrome and aging. | CCCCCC/C=C\C=C/CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC)OC(=O)CCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Aging",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, aging, and diabetic heart disease. The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, proton trap for oxidative phosphorylation that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCC(C)CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Aging",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts seizure, diabetes mellitus, and colorectal cancer. It impacts alzheimer's disease, stomach cancer, cardiovascular disease, and parkinson's disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C[C@H](O)[C@@H](O)CCCC(=O)OC[C@H](COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC | [
"Breast cancer",
"Seizure",
"Diabetes mellitus",
"Colorectal cancer",
"Alzheimer's Disease",
"Stomach cancer",
"Cardiovascular disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts aging, non-alcoholic fatty liver disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Diabetic heart disease",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts barth syndrome, non-alcoholic fatty liver disease, diabetic heart disease, and tangier disease. The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCC | [
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts barth syndrome and diabetic heart disease. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)CC | [
"Stabilizing cytochrome oxidase",
"Aging",
"Non-alcoholic fatty liver disease",
"Apoptosis",
"Tangier disease",
"Barth syndrome",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, stabilizing cytochrome oxidase that impacts tangier disease and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation and a apoptosis that impacts barth syndrome, diabetic heart disease, and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Cholesterol translocation",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage and a stabilizing mitochondrial structure, impacting both non-alcoholic fatty liver disease and barth syndrome. The molecule is a emulsifier, energy source, stabilizing cytochrome oxidase, apoptosis, nutritional supplement. The molecule is a surfactant and a membrane stabilizer, impacti... | CCCCC/C=C\C/C=C\CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Energy storage",
"Barth syndrome",
"Stabilizing mitochondrial structure",
"Emulsifier",
"Energy source",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Nutritional supplement",
"Tangier disease",
"surfactant",
"Diabetic heart disease",
"Membrane stabili... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation and a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts tangier disease and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts kwashiorkor, pulmonary edema, cholestasis, and hepatocellular carcinoma. The molecule is a carcinogen that impacts jaundice, cirrhosis, and hepatitis. It impacts liver disease, edema, pain, and abdominal pain. It impacts liver damage, reye's syndrome, vomiting, and cancer. | COc1cc(O)c2c(=O)cc(-c3ccc(O)cc3O)oc2c1CC=C(C)C | [
"Kwashiorkor",
"Pulmonary edema",
"Cholestasis",
"Hepatocellular carcinoma",
"Jaundice",
"Cirrhosis",
"Carcinogen",
"Hepatitis",
"Liver disease",
"Edema",
"Pain",
"Abdominal pain",
"Liver damage",
"Reye's syndrome",
"Vomiting",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the crf antagonist class of molecules. | CCOC(=O)c1c(CC)nn(-c2c(C)cc(Br)cc2C)c1S(C)(=O)=O | [
"crf antagonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a angiogenesis inhibitor and a cancer treatment. | Cc1ccc(C(=O)Nc2cc(C(F)(F)F)ncn2)cc1-c1cc2cnc(N)nc2c(-c2cccc(C#N)c2)c1O | [
"angiogenesis inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti inflammatory and is anti malarial. | OC(CC1NCCCC1O)CN1C=Nc2cc(Br)c(Cl)cc2C1 | [
"anti malarial",
"anti inflammatory"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory and a energy storage that impacts metabolic syndrome, cardiovascular disease, atherosclerosis, and pancreatitis. The molecule is a membrane stabilizer that affects cancer by impacting obesity. The molecule is a nutrient, a fat storage, and a energy source, and it impacts thyroxine treatme... | CCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCC(C)CC | [
"inflammatory",
"Metabolic syndrome",
"Energy storage",
"Cardiovascular disease",
"Atherosclerosis",
"Pancreatitis",
"Obesity",
"Cancer",
"Membrane stabilizer",
"Thyroxine treatment",
"nutrient",
"Fat storage",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | O=BO | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a angiogenesis inhibitor, a anti hiv, and anti cancer. | CN(C)C1CC23CCC4(O2)C2CC=C(c5ccc6cnccc6c5)C2(C)CCC4(Cl)CC3C(O)C1O | [
"angiogenesis inhibitor",
"anti cancer",
"anti hiv"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a kinase inhibitor and p38 map kinase inhibitor, and it impacts inflammatory disease treatment. | COc1ccc(-n2nc(C(C)(C)C)cc2NC=O)cc1 | [
"inflammatory disease treatment",
"kinase inhibitor",
"p38 map kinase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, aging, and barth syndrome. The molecule is a stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts tangier disease and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Diabetic heart disease",
"Aging",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Apoptosis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, fat storage that belongs to the thyroxine treatment class of molecules and impacts both obesity and atherosclerosis. The molecule is a energy storage and nutrient with an effect on cancer. The molecule is a inflammatory that impacts metabolic syndrome, cardiovascula... | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Obesity",
"Atherosclerosis",
"Membrane stabilizer",
"Thyroxine treatment",
"Energy source",
"Fat storage",
"Energy storage",
"nutrient",
"Cancer",
"Metabolic syndrome",
"Cardiovascular disease",
"inflammatory",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, stabilizing mitochondrial structure, apoptosis, cholesterol translocation that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, diabetic heart disease, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Diabetic heart disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, emulsifier, energy storage, grapefruit, minty, and chocolate. The molecule is a surfactant, membrane stabilizer, energy source, lemon, lime, and pepper. | C=CC1(C)CCC(C(=C)C)CC1C(=C)C | [
"grapefruit",
"nutrient",
"Emulsifier",
"minty",
"Energy storage",
"chocolate",
"surfactant",
"lemon",
"Membrane stabilizer",
"Energy source",
"lime",
"pepper"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and thyroxine treatment. The molecule is a nutrient that impacts metabolic syndrome, cardiovascular disease, and pancreatitis. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@@H](COCCCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC | [
"Atherosclerosis",
"Thyroxine treatment",
"Fat storage",
"nutrient",
"Metabolic syndrome",
"Cardiovascular disease",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts diabetes mellitus type 2, non-alcoholic fatty liver disease, alzheimer's disease, and parkinson's disease. | CC/C=C\C(O)C/C=C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OCCN)OC(=O)CCCCCCCCCCCCCC | [
"Diabetes mellitus type 2",
"Non-alcoholic fatty liver disease",
"nutrient",
"Alzheimer's Disease",
"Parkinson's disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source that impacts cardiovascular disease, heart failure, and breast cancer. It impacts inflammatory bowel disease, diabetes mellitus type 2, renal cell carcinoma, and celiac disease. | CCCCCCCCC=CCC=CCC=CCC(O)CC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Cardiovascular disease",
"Heart failure",
"Energy source",
"Breast cancer",
"Inflammatory bowel disease",
"Diabetes mellitus type 2",
"Renal cell carcinoma",
"Celiac disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, tangier disease, and non-alcoholic fatty liver disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts aging and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\CCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Diabetic heart disease",
"Stabilizing cytochrome oxidase",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a jak2 inhibitor, a btk inhibitor, and a pi3k inhibitor. | O=C1C(N2CC2)=CC(=O)c2c1n[n+]([O-])n2NC1CCC(c2ccccn2)CC1 | [
"jak2 inhibitor",
"btk inhibitor",
"pi3k inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure that impacts diabetic heart disease, non-alcoholic fatty liver disease, aging, and barth syndrome. The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation, stabilizing cytochrome oxidase that impacts tangier disease. | CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC)OC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCC | [
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a apoptosis that impacts non-alcoholic fatty liver disease, tangier disease, and aging. The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts diabetic heart disease and barth syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC | [
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts barth syndrome and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a proton trap for oxidative phosphorylation that impacts aging, tangier disease, and diabetic heart disease. | CCCCCC/C=C\C=C/CCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Barth syndrome",
"Non-alcoholic fatty liver disease",
"Stabilizing cytochrome oxidase",
"Aging",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, non-alcoholic fatty liver disease, diabetes mellitus type 2, and alzheimer's disease. | CC/C=C\C[C@H](O)/C=C/C=C\C=C\[C@H](O)C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"Parkinson's disease",
"nutrient",
"Non-alcoholic fatty liver disease",
"Diabetes mellitus type 2",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCC(=O)C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)[C@H](O)C[C@@H]1O)COP(=O)(O)OC[C@H](N)C(=O)O | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, cholesterol translocation, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a stabilizing cytochrome oxidase and a stabilizing mitochondrial structure that impacts barth syndrome, diabetic heart disease, and aging. | CCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCC | [
"Apoptosis",
"Cholesterol translocation",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Aging",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a proton trap for oxidative phosphorylation that impacts diabetic heart disease, non-alcoholic fatty liver disease, and aging. The molecule is a apoptosis, cholesterol translocation, stabilizing cytochrome oxidase that impacts tangier disease and barth syndrome. | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)CC | [
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Tangier disease",
"Apoptosis",
"Cholesterol translocation",
"Barth syndrome",
"Stabilizing cytochrome oxidase"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and thyroxine treatment. The molecule is a nutrient that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)OC[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCCCC/C=C\CCCCCC | [
"Atherosclerosis",
"Thyroxine treatment",
"Fat storage",
"Cardiovascular disease",
"Pancreatitis",
"nutrient",
"Metabolic syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, stabilizing mitochondrial structure, cholesterol translocation that impacts tangier disease and diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, and aging. | CCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCC(C)C | [
"Tangier disease",
"Apoptosis",
"Diabetic heart disease",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Proton trap for oxidative phosphorylation",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation that impacts aging, non-alcoholic fatty liver disease, barth syndrome, and diabetic heart disease. The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, apoptosis, stabilizing mitochondrial structure that impacts tangier disease. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCC(C)CC | [
"Aging",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, energy storage, membrane stabilizer that impacts cardiovascular disease, pancreatitis, and metabolic syndrome. The molecule is a fat storage and inflammatory with an effect on cancer. The molecule is a nutrient and belongs to the thyroxine treatment class of molecules, impacting both at... | CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC(C)C | [
"Energy source",
"Cardiovascular disease",
"Pancreatitis",
"Metabolic syndrome",
"Energy storage",
"Membrane stabilizer",
"Fat storage",
"Cancer",
"inflammatory",
"nutrient",
"Thyroxine treatment",
"Atherosclerosis",
"Obesity"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti arrhythmic and a anti ulcer, belonging to the anti bacterial class of molecules. | O=C(OCCN1CCCC1)c1nn(-c2ccccc2)c2c1CCc1cc(Cl)ccc1-2 | [
"anti arrhythmic",
"anti bacterial",
"anti ulcer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a cholesterol translocation that impacts tangier disease, diabetic heart disease, and aging. The molecule is a stabilizing mitochondrial structure, apoptosis, stabilizing cytochrome oxidase that impacts barth syndrome and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Tangier disease",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Aging",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing cytochrome oxidase that impacts aging. The molecule is a apoptosis that impacts non-alcoholic fatty liver disease, barth syndrome, diabetic heart disease, and tangier disease. | CCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Aging",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Apoptosis",
"Diabetic heart disease",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the fxr agonist class of molecules. | O=[N+]([O-])c1cccc(-c2cc(C3CC3)[nH]n2)c1 | [
"fxr agonist"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer, energy source, energy storage, nutrient, surfactant, emulsifier. | CNC[C@H](O)c1ccc(O)c(O)c1.Cl | [
"Membrane stabilizer",
"Energy source",
"Energy storage",
"nutrient",
"surfactant",
"Emulsifier"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, energy storage, food additive, stabilizing mitochondrial structure. The molecule is a energy source, cholesterol translocation, surfactant that impacts aging and diabetic heart disease. The molecule is a membrane stabilizer and a stabilizing cytochrome oxidase, impacting both non-alcoholic ... | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCC(C)C | [
"Apoptosis",
"Energy storage",
"food additive",
"Stabilizing mitochondrial structure",
"Energy source",
"Cholesterol translocation",
"surfactant",
"Aging",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Membrane stabilizer",
"Stabilizing cytochrome oxidase",
"Tangier disease... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a fat storage that impacts both atherosclerosis and pancreatitis. The molecule is a nutrient and thyroxine treatment, impacting both metabolic syndrome and cardiovascular disease. | CCCCCC/C=C\CCCCCCCC(=O)OC[C@@H](COC(=O)CCC/C=C\C/C=C\C/C=C\CCCCCCCC)OC(=O)CCCCCCCCCCC/C=C\CCCCCCCC | [
"Atherosclerosis",
"Pancreatitis",
"Fat storage",
"nutrient",
"Metabolic syndrome",
"Cardiovascular disease",
"Thyroxine treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient, membrane stabilizer, energy source, inflammatory that impacts metabolic syndrome and obesity. The molecule is a thyroxine treatment that impacts both cancer and pancreatitis. The molecule is a fat storage and a energy storage, impacting both atherosclerosis and cardiovascular disease. | CCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC(C)C | [
"nutrient",
"Metabolic syndrome",
"Membrane stabilizer",
"Energy source",
"inflammatory",
"Obesity",
"Cancer",
"Pancreatitis",
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"Cardiovascular disease",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, cholesterol translocation that impacts aging and diabetic heart disease. The molecule is a apoptosis and a proton trap for oxidative phosphorylation that impacts barth syndrome, tangier disease, and non-alcoholic fatty liver disease. | CCCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"Stabilizing mitochondrial structure",
"Aging",
"Stabilizing cytochrome oxidase",
"Cholesterol translocation",
"Diabetic heart disease",
"Barth syndrome",
"Apoptosis",
"Proton trap for oxidative phosphorylation",
"Tangier disease",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient and a thyroxine treatment that impacts atherosclerosis, pancreatitis, obesity, and cardiovascular disease. The molecule is a energy storage, a inflammatory, and a energy source. The molecule is a fat storage and a membrane stabilizer, impacting both metabolic syndrome and cancer. | CC(C)CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Atherosclerosis",
"nutrient",
"Thyroxine treatment",
"Pancreatitis",
"Obesity",
"Cardiovascular disease",
"Energy storage",
"inflammatory",
"Energy source",
"Fat storage",
"Metabolic syndrome",
"Cancer",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, stabilizing mitochondrial structure, cholesterol translocation, apoptosis that impacts diabetic heart disease. The molecule is a proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease, aging, barth syndrome, and tangier disease. | CC/C=C\C/C=C\C/C=C\C/C=C\CCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCCCC | [
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Cholesterol translocation",
"Apoptosis",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Barth syndrome",
"Proton trap for oxidative phosphorylation",
"Tangier disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts inflammatory bowel disease, celiac disease, breast cancer, and cardiovascular disease. The molecule is a energy source that impacts renal cell carcinoma, heart failure, and diabetes mellitus type 2. | CCC=CCCC(O)C(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Inflammatory bowel disease",
"Celiac disease",
"Breast cancer",
"Cardiovascular disease",
"Energy source",
"Renal cell carcinoma",
"Heart failure",
"Diabetes mellitus type 2"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a wnt pathway inhibitor. | CCC(=O)Nc1cncc(-c2cc3c(-c4nc5nccc(-c6ccc(C)s6)c5[nH]4)n[nH]c3cn2)c1 | [
"wnt pathway inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase and a apoptosis that impacts barth syndrome, diabetic heart disease, and aging. The molecule is a proton trap for oxidative phosphorylation, cholesterol translocation, stabilizing mitochondrial structure that impacts tangier disease and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC | [
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Diabetic heart disease",
"Apoptosis",
"Aging",
"Proton trap for oxidative phosphorylation",
"Cholesterol translocation",
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a hazardous air pollutant and a water pollutant, belonging to both the hepatotoxic agent and hepatotoxin classes of molecules, and it impacts both nausea and coma. The molecule is a hepatoprotective, refrigerant, air pollutant that belongs to the anesthetic class of molecules and impacts both vomiting a... | C=CCCO | [
"hepatotoxic agent",
"Nausea",
"Hazardous air pollutant",
"Coma",
"Hepatotoxin",
"Water pollutant",
"hepatoprotective",
"Vomiting",
"refrigerant",
"Dizziness",
"anesthetic",
"Air pollutant"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts aging, diabetic heart disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging",
"Diabetic heart disease",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation and a stabilizing cytochrome oxidase that impacts non-alcoholic fatty liver disease, barth syndrome, and tangier disease. The molecule is a cholesterol translocation, apoptosis, stabilizing mitochondrial structure that impacts diabetic heart disease and aging. | CCCCCCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCC(C)C)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCC(C)C | [
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Tangier disease",
"Diabetic heart disease",
"Cholesterol translocation",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts parkinson's disease, diabetes mellitus type 2, non-alcoholic fatty liver disease, and alzheimer's disease. | CCCCC/C=C\C/C=C\CCCCCCCCCC(=O)O[C@H](CO/C=C\CCCCCCCCCCCCCCCC)COP(=O)(O)OCCN | [
"Parkinson's disease",
"Diabetes mellitus type 2",
"nutrient",
"Non-alcoholic fatty liver disease",
"Alzheimer's Disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ido inhibitor that impacts cancer treatment. | N#Cc1ccc(CC(=O)Nc2ccccc2N(CCC(F)(F)F)C2CCCCC2)cc1 | [
"ido inhibitor",
"cancer treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, proton trap for oxidative phosphorylation, stabilizing cytochrome oxidase that impacts diabetic heart disease and tangier disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts aging, non-alcoholic fatty liver disease, and barth syndrome. | CCCCCCCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC(C)CC)OC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCCCCCC(C)C | [
"Cholesterol translocation",
"Diabetic heart disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing cytochrome oxidase",
"Aging",
"Apoptosis",
"Non-alcoholic fatty liver disease",
"Barth syndrome",
"Stabilizing mitochondrial structure"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a proton trap for oxidative phosphorylation, apoptosis, cholesterol translocation, stabilizing mitochondrial structure that impacts barth syndrome. The molecule is a stabilizing cytochrome oxidase that impacts diabetic heart disease, tangier disease, aging, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCC/C=C\C/C=C\C/C=C\CC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CCCCC)OC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Apoptosis",
"Cholesterol translocation",
"Stabilizing mitochondrial structure",
"Stabilizing cytochrome oxidase",
"Diabetic heart disease",
"Tangier disease",
"Aging",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a adrenergic agent and is both anti hiv and belongs to the beta-adrenergic antagonist and anti viral agent classes of molecules. The molecule is a ec 1.17.3.2 (xanthine oxidase) inhibitor, a anti tumor, anti herpetic, anti sarcomic, and pesticide. | C[C@@H]1O[C@@H](Oc2cc(O)c3c(=O)c(O[C@@H]4O[C@H](CO[C@@H]5O[C@H](CO[C@@H]6O[C@H](CO)[C@@H](O)[C@H](O)[C@H]6O)[C@@H](O)[C@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)c(-c4ccc(O)cc4)oc3c2)[C@H](O)[C@H](O)[C@H]1O | [
"adrenergic agent",
"beta-adrenergic antagonist",
"anti viral agent",
"anti HIV",
"anti herpetic",
"anti sarcomic",
"EC 1.17.3.2 (xanthine oxidase) inhibitor",
"pesticide",
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti biotic member of the anti bacterial class. | COc1ccc(COC(=O)C2=C(C)C(OC)SC3C(NC(=O)Cc4ccccc4C(=O)OCc4ccc(OC)cc4)C(=O)N23)cc1 | [
"anti bacterial",
"anti biotic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti angiogenic class of molecules. | Cc1ccc(F)c(NC(=O)Nc2ccc(-c3c(C(=O)NCCCN4CCCC4)cn4ncnc(N)c34)cc2)c1 | [
"anti angiogenic"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It has an effect on breast cancer, and impacts cardiovascular disease, renal cell carcinoma, and diabetes mellitus type 2. The molecule is a energy source that impacts inflammatory bowel disease, heart failure, and celiac disease. | CCCCCCCC(O)CCC(=O)OC(CC(=O)[O-])C[N+](C)(C)C | [
"Breast cancer",
"Cardiovascular disease",
"Renal cell carcinoma",
"Diabetes mellitus type 2",
"Inflammatory bowel disease",
"Heart failure",
"Celiac disease",
"Energy source"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a signalling molecule, energy source, energy storage, emulsifier, surfactant, membrane stabilizer. | C=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C | [
"signalling molecule",
"Energy source",
"Energy storage",
"Emulsifier",
"surfactant",
"Membrane stabilizer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient that impacts both cardiovascular disease and metabolic syndrome. The molecule is a fat storage and thyroxine treatment, impacting both atherosclerosis and pancreatitis. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COC(=O)CCCCCCCCCCCCCCCCC | [
"Cardiovascular disease",
"Metabolic syndrome",
"nutrient",
"Thyroxine treatment",
"Fat storage",
"Atherosclerosis",
"Pancreatitis"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It belongs to the anti proliferative class of molecules. | Cc1ncc(C(=O)Nc2cc(C(C)(C)C)on2)cc1-n1cc(-c2cncc(N(C)CCN(C)C)c2)nn1 | [
"anti proliferative"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy source, energy storage, and inflammatory that has an effect on cancer and impacts both obesity and pancreatitis. The molecule is a nutrient and membrane stabilizer, and it impacts cardiovascular disease. The molecule is a fat storage that impacts thyroxine treatment, atherosclerosis, and metabo... | CCCCCCCCCCCCCCCCCCCC(=O)O[C@@H](COC(=O)CCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCC(C)CC | [
"Energy source",
"Cancer",
"Energy storage",
"inflammatory",
"Obesity",
"Pancreatitis",
"nutrient",
"Membrane stabilizer",
"Cardiovascular disease",
"Thyroxine treatment",
"Atherosclerosis",
"Metabolic syndrome",
"Fat storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CCC1CC(=O)C(O)=C1C | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure and a cholesterol translocation that impacts non-alcoholic fatty liver disease, aging, and tangier disease. The molecule is a stabilizing cytochrome oxidase, apoptosis, proton trap for oxidative phosphorylation that impacts diabetic heart disease and barth syndrome. | CCCCCCCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCC | [
"Non-alcoholic fatty liver disease",
"Stabilizing mitochondrial structure",
"Aging",
"Cholesterol translocation",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Barth syndrome"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a psychiatric treatment and a serotonin reuptake inhibitor. | CNCCCCc1cc2c(c(-c3ccc(F)cc3)c1C#N)COC2 | [
"psychiatric treatment",
"serotonin reuptake inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is both a pde4 inhibitor and a phosphodiesterase inhibitor. | CN(C)C1(C(=O)NC2CCC(NC(=O)c3cc(F)cnc3Oc3cccc(-c4ccc(O)cc4CN4CCOCC4)c3)CC2)CC1 | [
"pde4 inhibitor",
"phosphodiesterase inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a phytoalexin and belongs to the pesticide class of molecules. | CCCSSSCC(C)C | [
"phytoalexin",
"pesticide"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is anti microbial. | CC(=O)NCC1C(NC(=O)C(=NOC(C)(C)C(=O)O)c2csc(N)n2)C(=O)N1S(=O)(=O)O | [
"anti microbial"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti hypertensive member of the angiotensin ii antagonist class. | CCCCc1nc2cscc2n1Cc1ccc(-c2ccccc2-c2nnnn2C(c2ccccc2)(c2ccccc2)c2ccccc2)cc1 | [
"angiotensin ii antagonist",
"anti hypertensive"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts psychiatric treatment. | Cc1cc(Cl)cnc1C1(F)CCCN(C(=O)c2cnnc(Cl)c2)C1 | [
"psychiatric treatment"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cetp inhibitor. | CCOC(=O)C(C)CCN1CCCC(N(Cc2cc(C(F)(F)F)cc(C(F)(F)F)c2)c2nnn(C)n2)c2cc(C)c(C(F)(F)F)cc21 | [
"cetp inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a cholesterol translocation, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts aging and diabetic heart disease. The molecule is a apoptosis and a stabilizing mitochondrial structure that impacts tangier disease, barth syndrome, and non-alcoholic fatty liver disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC)OC(=O)CCCC/C=C\C/C=C\C/C=C\C/C=C\CC | [
"Cholesterol translocation",
"Stabilizing cytochrome oxidase",
"Aging",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Tangier disease",
"Apoptosis",
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Non-alcoholic fatty liver disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a membrane stabilizer that affects cancer by impacting pancreatitis, cardiovascular disease, obesity, and metabolic syndrome. The molecule is a fat storage and nutrient, and it impacts atherosclerosis. The molecule is a energy source, inflammatory, thyroxine treatment, energy storage. | CCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCCCCCCCCCCCC(C)CC)COC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"Pancreatitis",
"Membrane stabilizer",
"Cardiovascular disease",
"Obesity",
"Cancer",
"Metabolic syndrome",
"Atherosclerosis",
"Fat storage",
"nutrient",
"Energy source",
"inflammatory",
"Thyroxine treatment",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
It impacts cardiovascular disease, colorectal cancer, seizure, and alzheimer's disease. It has an effect on stomach cancer, and impacts diabetes mellitus, parkinson's disease, and breast cancer. | CC/C=C\C/C=C\C/C=C\CCCCCCCC(=O)O[C@H](COC(=O)CCC/C=C\C/C=C\C/C=C\C/C=C\CC(O)CCC)COP(=O)(O)O[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@H](O)[C@H]1O | [
"Cardiovascular disease",
"Colorectal cancer",
"Seizure",
"Alzheimer's Disease",
"Diabetes mellitus",
"Parkinson's disease",
"Stomach cancer",
"Breast cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage that impacts aging, non-alcoholic fatty liver disease, and tangier disease. The molecule is a proton trap for oxidative phosphorylation, a cholesterol translocation, and a apoptosis, it impacts barth syndrome and is smooth. The molecule is a emulsifier, stabilizing cytochrome oxidase, m... | CCC(C)CCCCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCC(C)C | [
"Aging",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Energy storage",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Apoptosis",
"Smooth",
"Emulsifier",
"Stabilizing cytochrome oxidase",
"Membrane stabilizer",
"Nutritional supplement... | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a anti tumor. | CCc1c2c(nc3cccc(C#CCN(C)C)c13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC | [
"anti tumor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a nutrient. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](N)C(=O)O)OC(=O)CCCCCCC/C=C\CCCC | [
"nutrient"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts non-alcoholic fatty liver disease and tangier disease. The molecule is a apoptosis and a cholesterol translocation that impacts diabetic heart disease, barth syndrome, and aging. | CCCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCC(C)C | [
"Stabilizing cytochrome oxidase",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Apoptosis",
"Diabetic heart disease",
"Barth syndrome",
"Cholesterol translocation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis and a stabilizing cytochrome oxidase that impacts tangier disease, non-alcoholic fatty liver disease, and aging. The molecule is a stabilizing mitochondrial structure, proton trap for oxidative phosphorylation, cholesterol translocation that impacts barth syndrome and diabetic heart disease. | CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)OC(=O)CCCCCCC/C=C\CCCCCC | [
"Tangier disease",
"Non-alcoholic fatty liver disease",
"Aging",
"Apoptosis",
"Stabilizing cytochrome oxidase",
"Stabilizing mitochondrial structure",
"Proton trap for oxidative phosphorylation",
"Barth syndrome",
"Cholesterol translocation",
"Diabetic heart disease"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a ezh2 inhibitor that impacts cancer treatment. | CCN(c1cc(-c2cnc(OC)cn2)cc(C(=O)NCc2c(C(C)C)cc(C)[nH]c2=O)c1C)C1CCOCC1 | [
"cancer treatment",
"ezh2 inhibitor"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a stabilizing mitochondrial structure, stabilizing cytochrome oxidase, proton trap for oxidative phosphorylation that impacts barth syndrome and diabetic heart disease. The molecule is a apoptosis and a cholesterol translocation that impacts non-alcoholic fatty liver disease, tangier disease, and aging. | CC/C=C\C/C=C\C/C=C\CCCCCCCCCC(=O)OC[C@H](COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC)OC(=O)CCCCCCCCC/C=C\C/C=C\CCCCC | [
"Stabilizing mitochondrial structure",
"Barth syndrome",
"Stabilizing cytochrome oxidase",
"Proton trap for oxidative phosphorylation",
"Diabetic heart disease",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Aging",
"Apoptosis",
"Cholesterol translocation"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, energy storage, nutrient, energy source that impacts obesity and metabolic syndrome. The molecule is a fat storage that impacts both atherosclerosis and pancreatitis. The membrane stabilizer molecule affects cancer, impacts cardiovascular disease, and is thyroxine treatment. | CC(C)CCCCCCCCCCCCCCCCC(=O)OC[C@H](COC(=O)CCCCCCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCCCCCCC(C)C | [
"inflammatory",
"Energy storage",
"nutrient",
"Obesity",
"Metabolic syndrome",
"Energy source",
"Atherosclerosis",
"Fat storage",
"Pancreatitis",
"Membrane stabilizer",
"Thyroxine treatment",
"Cardiovascular disease",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a energy storage and nutrient, belonging to the thyroxine treatment class of molecules, and impacts atherosclerosis, metabolic syndrome, and obesity. The molecule is a energy source, a fat storage, and a membrane stabilizer. The molecule is a inflammatory that impacts cardiovascular disease, pancreatiti... | CCCCCCCCCCCCCC(=O)O[C@H](COC(=O)CCCCCCCCCCC(C)C)COC(=O)CCCCCCCCC(C)CC | [
"Energy storage",
"Atherosclerosis",
"Thyroxine treatment",
"Metabolic syndrome",
"nutrient",
"Obesity",
"Energy source",
"Fat storage",
"Membrane stabilizer",
"Cardiovascular disease",
"inflammatory",
"Pancreatitis",
"Cancer"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a apoptosis, proton trap for oxidative phosphorylation, stabilizing mitochondrial structure that impacts diabetic heart disease and non-alcoholic fatty liver disease. The molecule is a stabilizing cytochrome oxidase and a cholesterol translocation that impacts tangier disease, barth syndrome, and aging. | CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O[C@H](COC(=O)CCCCCCC/C=C\C/C=C\CCCCC)COP(=O)(O)OC[C@@H](O)COP(=O)(O)OC[C@@H](COC(=O)CCCCCCCCCCCCC)OC(=O)CCCCCCCCCCCCCCCCC | [
"Apoptosis",
"Diabetic heart disease",
"Proton trap for oxidative phosphorylation",
"Stabilizing mitochondrial structure",
"Non-alcoholic fatty liver disease",
"Tangier disease",
"Stabilizing cytochrome oxidase",
"Barth syndrome",
"Cholesterol translocation",
"Aging"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
The molecule is a inflammatory, a nutrient, and a energy source that impacts both cancer and metabolic syndrome, and is thyroxine treatment. It impacts cardiovascular disease, obesity, and pancreatitis. The molecule is a membrane stabilizer, a fat storage, and a energy storage, and it impacts atherosclerosis. | CCC(C)CCCCCCCCCCCCCCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCCCC(C)C)OC(=O)CCCCCCCCCCCC(C)C | [
"inflammatory",
"nutrient",
"Energy source",
"Cancer",
"Metabolic syndrome",
"Thyroxine treatment",
"Cardiovascular disease",
"Obesity",
"Pancreatitis",
"Atherosclerosis",
"Membrane stabilizer",
"Fat storage",
"Energy storage"
] | {
"Actives": null,
"Approval Date": null,
"Brand Name": null,
"Indication": null,
"PubChem CIDs": null
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.